Lithium nephrotoxicity

被引：57

作者：

Azab A.N. ^{[1
]}

Shnaider A. ^{[2
]}

Osher Y. ^{[3
]}

Wang D. ^{[3
]}

Bersudsky Y. ^{[3
]}

Belmaker R.H. ^{[3
,4
]}

机构：

[1] School for Community Health Professions, Soroka University Medical Center, Beer-Sheva

[2] Nephrology Department, Soroka University Medical Center, Beer-Sheva

[3] Bipolar Disorders Clinic, Beer-Sheva Mental Health Center, Ben-Gurion University of the Negev, Beer-Sheva

[4] Bipolar Disorders Clinic, Hadassah Medical Center, Hadassah University Hospital, Jerusalem

来源：

International Journal of Bipolar Disorders | / 3卷 / 1期

关键词：

Bipolar disorder; Creatinine; Kidney; Lithium; Nephrotoxicity; Suicide;

D O I：

10.1186/s40345-015-0028-y

中图分类号：

学科分类号：

摘要：

Reports of toxic effects on the kidney of lithium treatment emerged very soon after lithium therapy was introduced. Lithium-induced nephrogenic diabetes insipidus is usually self-limiting or not clinically dangerous. Some reports of irreversible chronic kidney disease and renal failure were difficult to attribute to lithium treatment since chronic kidney disease and renal failure exist in the population at large. In recent years, large-scale epidemiological studies have convincingly shown that lithium treatment elevates the risk of chronic kidney disease and renal failure. Most patients do not experience renal side effects. The most common side effect of polyuria only weakly predicts increasing creatinine or reduced kidney function. Among those patients who do experience decrease in creatinine clearance, some may require continuation of lithium treatment even as their creatinine increases. Other patients may be able to switch to a different mood stabilizer medication, but kidney function may continue to deteriorate even after lithium cessation. Most, but not all, evidence today recommends using a lower lithium plasma level target for long-term maintenance and thereby reducing risks of severe nephrotoxicity. © 2015, Azab et al.

引用

页数：9

共 46 条

[1]

Aiff H., Attman P.O., Aurell M., Bendz H., Schon S., Svedlund J., The impact of modern treatment principles may have eliminated lithium-induced renal failure, J Psychopharmacol, 28, pp. 151-154, (2014)

[2]

Aiff H., Attman P.O., Aurell M., Bendz H., Schon S., Svedlund J., End-stage renal disease associated with prophylactic lithium treatment, Eur Neuropsychopharmacol, 24, pp. 540-544, (2014)

[3]

Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification, Am J Kidney Dis, 39, pp. 1-266, (2002)

[4]

Angrist B.M., Gershon S., Levitan S.J., Blumberg A.G., Lithium-induced diabetes insipidus-like syndrome, Compr Psychiatry, 11, 2, pp. 141-146, (1970)

[5]

Aprhamian I., Santos F.S., dos Santod B., Talib L., Diniz B.S., Radanovic M., Et al., Long-term, low-dose lithium treatment does not impair renal function in the elderly: a 2-year randomized placebo-controlled trial followed by a single-blind extension, J Clin Psychiatry, 7, pp. 672-678, (2014)

[6]

Baylis P.H., Heath D.A., Water disturbances in patients treated with oral lithium carbonate, Ann Intern Med, 88, 5, pp. 607-609, (1978)

[7]

Bedford J.J., Leader J.P., Jing R., Walker L.J., Klein J.D., Sands J.M., Et al., Amiloride restores renal medullary osmolytes in lithium-induced nephrogenic diabetes insipidus, Am J Physiol Renal Physiol, 294, 4, pp. 812-820, (2008)

[8]

Belmaker R.H., Bipolar disorder, N Engl J Med, 351, 5, pp. 476-486, (2004)

[9]

Belmaker R.H., Lurisadone and bipolar disorder, Am J Psychiatry, 171, pp. 131-133, (2014)

[10]

Belmaker R., Bersudsky Y., Agam G., Individual differences and evidence-based psychopharmacology, BMC Med, 10, (2012)

← 1 2 3 4 5 →